Apolipoprotein-E genotype and human immunodeficiency virus-associated neurocognitive disorder: The modulating effects of older age and disease severity

Neurobehavioral HIV Medicine

Volumn 5, Issue 1, 2013, Pages 11-22

  Panos, Stella E ^a,b   Hinkin, Charles H ^a,b   Singer, Elyse J ^a   Thames, April D ^a,b   Patel, Sapna M ^a,b   Sinsheimer, Janet S ^a   Del Re, A C ^c   Gelman, Benjamin B ^d   Morgello, Susan ^e   Moore, David J ^f   Levine, Andrew J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c STANFORD UNIVERSITY   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Apolipoprotein E; Human immunodeficiency virus; Neurocognition

Indexed keywords

APOLIPOPROTEIN E;

ADULT; AGING; ALLELE; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; COGNITION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HETEROZYGOTE; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TEST; NONHUMAN; RISK FACTOR; WORKING MEMORY;

EID: 84880320472     PISSN: None     EISSN: 11791497     Source Type: Journal    
DOI: 10.2147/NBHIV.S39573     Document Type: Article

References (64)

1. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA. 1998;280(17):1497-1503.
2. Centers for Disease Control. HIV/AIDS Surveillance Report, 2005. Atlanta, GA: US Department of Health and Human Services; 2007. Available from: http://www.cdc.gov/hiv/topics/surveillance/resources/reports/2005report/pdf/2005surveillancereport.pdf. Accessed January 13, 2013.
3. Dilley JW, Schwarcz S, Loeb L, Hsu L, Nelson K, Scheer S. The decline of incident cases of HIV-associated neurological disorders in San Francisco, 1991-2003. AIDS. 2005;19(6):634-635.
4. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology. 2010;75(23):2087-2096.
5. Sacktor N. The epidemiology of human immunodeficiency virus-associated neurological disease in the era of highly active antiretroviral therapy. J Neurovirol. 2002;8 Suppl 2:115-121.
6. Valcour VG, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology. 2004;63(5):822-827.
7. Chuang YF, Hayden KM, Norton MC, et al. Association between APOE epsilon4 allele and vascular dementia: the Cache County study. Dement Geriatr Cogn Disord. 2010;29(3):248-253.
8. Liu X, Li L, Liu F, et al. ApoE gene polymorphism and vascular dementia in Chinese population: a meta-analysis. J Neural Transm. 2012;119(3):387-394.
9. Teasdale GM, Murray GD, Nicoll JA. The association between APOE epsilon4, age and outcome after head injury: a prospective cohort study. Brain. 2005;128(Pt 11):2556-2561.
10. Teasdale GM, Nicoll JA, Murray G, Fiddes M. Association of apolipoprotein-E polymorphism with outcome after head injury. Lancet. 1997;350(9084):1069-1071.
11. Jarvik L, LaRue A, Blacker D, et al. Children of persons with Alzheimer disease: what does the future hold? Alzheimer Dis Assoc Disord. 2008;22(1):6-20.
12. Drenos F, Kirkwood TB. Selection on alleles affecting human longevity and late-life disease: the example of apolipoprotein-E. PLoS One. 2010;5(4):e10022.
13. Jofre-Monseny L, Minihane AM, Rimbach G. Impact of apoE genotype on oxidative stress, inflammation and disease risk. Mol Nutr Food Res. 2008;52(1):131-145.
14. Kulminski AM, Culminskaya I, Ukraintseva SV, et al. Trade-off in the effects of the apolipoprotein-E polymorphism on the ages at onset of CVD and cancer influences human lifespan. Aging Cell. 2011;10(3):533-541.
15. Moore RJ, Chamberlain RM, Khuri FR. Apolipoprotein E and the risk of breast cancer in African-American and non-Hispanic white women. A review. Oncology. 2004;66(2):79-93.
16. Smith JD. Apolipoproteins and aging: emerging mechanisms. Ageing Res Rev. 2002;1(3):345-365.
17. Bedlack RS, Strittmatter MD, Morgenlander JC. Apolipoprotein E and neuromuscular disease: a critical review of the literature. Arch Neurol. 2000;57:1561-1565.
18. Burt TD, Agan BK, Marconi VC, et al. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A. 2008;105(25):8718-8723.
19. Hill JM, Bhattacharjee PS, Neumann DM. Apolipoprotein E alleles can contribute to the pathogenesis of numerous clinical conditions including HSV-1 corneal disease. Exp Eye Res. 2007;84(5):801-811.
20. Jayasuriya AN, Itzhaki RF, Wozniak MA, et al. Apolipoprotein E-epsilon 4 and recurrent genital herpes in individuals co-infected with herpes simplex virus type 2 and HIV. Sex Transm Infect. 2008;84(7):516-517.
21. Kuhlmann I, Minihane AM, Huebbe P, Nebel A, Rimbach G. Apolipoprotein E genotype and hepatitis C, HIV and herpes simplex disease risk: a literature review. Lipids Health Dis. 2010;9:8.
22. Vitek MP, Brown CM, Colton CA. APOE genotype-specific differences in the innate immune response. Neurobiol Aging. 2009;30(9): 1350-1360.
23. Corder EH, Robertson KR, Lannfelt L, et al. HIV-infected subjects with E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med. 1998;4(10):1182-1184.
24. Andres MA, Feger U, Nath A, Munsaka S, Jiang CS, Chang L. APOE epsilon 4 allele and CSF APOE on cognition in HIV-infected subjects. J Neuroimmune Pharmacol. 2011;6(3):389-398.
25. Chang L, Andres M, Sadino J, et al. Impact of apolipoprotein-E epsilon4 and HIV on cognition and brain atrophy: antagonistic pleiotropy and premature brain aging. Neuroimage. 2011;58(4):1017-1027.
26. Joska JA, Combrinck M, Valcour VG, et al. Association between apolipoprotein-E4 genotype and human immunodeficiency virus-associated dementia in younger adults starting antiretroviral therapy in South Africa. J Neurovirol. 2010;16(5):377-383.
27. Pemberton LA, Stone E, Price P, van Bockxmeer F, Brew BJ. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med. 2008;9(8):677-680.
28. Pomara N, Belzer KD, Silva R, Cooper TB, Sidtis JJ. The apolipoprotein-E epsilon4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge. Psychopharmacology (Berl). 2008;201(1):125-135.
29. Spector SA, Singh KK, Gupta S, et al. APOE e4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS. 2010;24(10):1471-1479.
30. Sun B, Abadjian L, Rempel H, Calosing C, Rothlind J, Pulliam L. Peripheral biomarkers do not correlate with cognitive impairment in highly active antiretroviral therapy-treated subjects with human immunodeficiency virus type 1 infection. J Neurovirol. 2010;16(2):115-124.
31. Valcour VG, Shikuma C, Shiramizu B, et al. Age, apolipoprotein-E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157(1-2):197-202.
32. Jarvik GP, Austin MA, Fabsitz RR, et al. Genetic influences on age-related change in total cholesterol, low density lipoprotein-cholesterol, and triglyceride levels: longitudinal apolipoprotein-E genotype effects. Genet Epidemiol. 1994;11(4):375-384.
33. Kulminski A, Culminskaya I, Arbeev K, Ukraintseva S, Arbeeva L, Yashin AI. Trade-off in the effect of the APOE gene on the ages at onset of CVD and cancer across ages, gender, and human generations. Rejuvenation Res. October 25, 2012. [Epub ahead of print.]
34. Corder EH, Galeazzi L, Franceschi C, et al. Differential course of HIV-1 infection and apolipoprotein-E polymorphism. Proc Natl Acad Sci U S A. 2008;105(46):E87.
35. Morgello S, Gelman BB, Kozlowski PB, et al. The National NeuroAIDS Tissue Consortium: a new paradigm in brain banking with an emphasis on infectious disease. Neuropathol Appl Neurobiol. 2001;27(4): 326-335.
36. American Academy of Neurology. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology. 1991;41(6):778-785.
37. Levine AJ, Sinsheimer JS, Bilder R, Shapshak P, Singer EJ. Functional polymorphisms in dopamine-related genes: effect on neurocognitive functioning in HIV+ adults. J Clin Exp Neuropsychol. 2012;34(1): 78-91.
38. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18): 1789-1799.
39. Wilkinson GS. The Wide Range Achievement Test: Manual, 3rd ed. Wilmington, DE: Wide Range; 1993.
40. Thames AD, Foley JM, Panos SE, Singer EJ, El-Saden S, Hinkin CH. Cognitve reserve masks neurobehavioral expression of immunodeficiency virus-associated neurological disorder in older patients. Neurobehav HIV Med. 2011;3:87-93.
41. Hasin DS, Trautman KD, Miele GM, Samet S, Smith M, Endicott J. Psychiatric Research Interview for Substance and Mental Disorders (PRISM): reliability for substance abusers. Am J Psychiatry. 1996;153(9):1195-1201.
42. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
43. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein-E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278(16):1349-1356.
44. Teruel BM, Rodriguez JJ, McKeigue P, et al. Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case-control study. BMC Med Genet. 2011;12:43.
45. Ettenhofer ML, Hinkin CH, Castellon SA, et al. Aging, neurocognition, and medication adherence in HIV infection. Am J Geriatr Psychiatry. 2009;17(4):281-290.
46. Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944-1950.
47. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein-E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol. 2004;157(1-2):197-202.
48. Caselli RJ, Dueck AC, Osborne D, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361(3):255-263.
49. Liu F, Pardo LM, Schuur M, et al. The apolipoprotein-E gene and its age-specific effects on cognitive function. Neurobiol Aging. 2010;31(10): 1831-1833.
50. Benjamini Y, Hochberg Y. The adaptive control of the false discovery rate in multiple comparison problems. J Educ Behav Stat. 2000;25(1): 60-83.
51. Satz P. Brain reserve capacity on symptom onset after brain injury. A formulation and review of evidence for threshold theory. Neuropsychology. 1993;7(3):273-295.
52. Satz P, Morgenstern H, Miller EN, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS cohort study (MACS). J Acquir Immune Defic Syndr. 1993;6(5):503-511.
53. Stern Y. Cognitive reserve and Alzheimer's disease. Alzheimer Dis Assoc Disord. 2006;20:S69-S74.
54. Tuminello ER, Han SD. The apolipoprotein e antagonistic pleiotropy hypothesis: review and recommendations. Int J Alzheimers Dis. 2011;2011:726197.
55. Yu YW, Lin CH, Chen SP, Hong CJ, Tsai SJ. Intelligence and event-related potentials for young female human volunteer apolipoprotein-E epsilon4 and non-epsilon4 carriers. Neurosci Lett. 2000;294(3): 179-181.
56. Wright RO, Hu H, Silverman EK, et al. Apolipoprotein E genotype predicts 24-month bayley scales infant development score. Pediatr Res. 2003;54(6):819-825.
57. Valcour VG, Shiramizu B, Shikuma C. Frequency of apolipoprotein-E4 among older compared with younger HIV patients: support for detrimental effect of E4 on survival. Proc Natl Acad Sci U S A. 2008;105(41): E66.
58. Battery AIT. Manual of Directions and Scoring. Washington, DC: War Department, Adjutant General's Office; 1944.
59. Grant EA, Berg DA. A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card sorting problem. J Exp Psychol. 1948;38(4):404-411.
60. Heaton RK. A Manual for the Wisconsin Card Sorting Test. Odessa, FL: Psychological Assessment Resources; 1981.
61. Wechsler D. Wechsler Adult Intelligence Scale-III. San Antonio, TX: The Psychological Corporation; 1997.
62. Wiens AN, Fuller KH, Crossen JR. Paced Auditory Serial Addition Test: adult norms and moderator variables. J Clin Exp Neuropsychol. 1997;19(4):473-483.
63. Shapiro AM, Benedict RH, Schretlen D, Brandt J. Construct and concurrent validity of the Hopkins Verbal Learning Test-Revised. Clin Neuropsychol. 1999;13(3):348-358.
64. Benedict RHB, Schretlen D, Groninger L, Dobraski M. Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychol Assess. 1996;8(2):145-153.